Specialty market
China Cancer Treatment Market Outlook 2026
China's oncology market reached USD 78.4 billion in 2025 with a 12.1% CAGR through 2030, driven by rising incidence (4.8M new cases per year), proton therapy capacity rollout, and rapid CAR-T and immunotherapy adoption.
Market size, 2021–2030
Mainland China oncology — public and private spending on cancer treatment.
| Year | Market size (USD) | Status |
|---|---|---|
| 2021 | USD 44.5 billion | Historical |
| 2022 | USD 52.2 billion | Historical |
| 2023 | USD 60.8 billion | Historical |
| 2024 | USD 69.2 billion | Historical |
| 2025 | USD 78.4 billion | Latest actual |
| 2026 | USD 87.9 billion | Forecast |
| 2030 | USD 138.6 billion | Forecast |
Demand drivers
- New cancer cases in China: ~4.82 million per year (2022 GLOBOCAN estimate) — the world's largest single-country cohort.
- NMPA-approved CAR-T (Yescarta/relmacabtagene, Carvykti/ciltacabtagene autoleucel) priced at ~1/3 of US.
- Proton therapy: 6 operational centres in 2026, including the world's only dual proton + heavy-ion centre in Shanghai.
- Checkpoint inhibitor adoption: ~14 domestic anti-PD-1/PD-L1 drugs approved, sharply lower priced vs imports.
Supply-side landscape
- Top centres: Sun Yat-sen University Cancer Centre, CAMS Cancer Hospital (National Cancer Centre), Fudan University Shanghai Cancer Centre, Peking University Cancer Hospital, West China Hospital.
- Proton therapy centres: Shanghai Proton & Heavy Ion Centre, Wanjie (Shandong), Hwa Mei (Hangzhou), CAMS Beijing, plus commissioning centres in Guangzhou and Shenzhen.
- International second-opinion programmes are mature at SYSUCC, CAMS, Fudan Cancer — 7–10 day turnaround for USD 800–1,800.
Risks & headwinds
- Drug-access disparity: some imported targeted therapies have multi-month NMPA approval lag vs FDA.
- Clinical-trial inclusion criteria for international patients vary by site and protocol.
- Cost of immunotherapy + targeted combinations can still reach USD 80,000–200,000 per year despite Chinese pricing advantage.
Notable providers
Sun Yat-sen University Cancer Centre
China's top cancer-only centre; strong nasopharyngeal cancer and head-and-neck programme.
Class ACAMS Cancer Hospital (National Cancer Centre)
Proton therapy, integrated oncology, national reference for cancer surgery.
Class AFudan University Shanghai Cancer Centre
Breast, GI, lung — high-volume specialised centre.
Shanghai Proton and Heavy Ion Centre
World's only dual proton + carbon-ion centre, largest treated-patient cohort in mainland China.
Related on this site
Specialty hubFull specialty pillar page
Frequently asked
- How big is the China cancer treatment market in 2026?
- USD 78.4 billion in 2025, forecast to USD 138.6 billion by 2030 (12.1% CAGR). The growth is concentrated in immunotherapy (PD-1/PD-L1), CAR-T cell therapy, proton therapy and precision oncology.
- Is proton therapy available in China?
- Yes — 6 operational centres in 2026 led by the Shanghai Proton and Heavy Ion Centre (world's only dual proton + carbon-ion programme). Cost is USD 35,000–75,000 all-in for a 6-week course vs USD 120,000–250,000 in the US.
- Can international patients access CAR-T cell therapy in China?
- Yes — Yescarta (relmacabtagene) and Carvykti (ciltacabtagene autoleucel) are NMPA-approved for selected lymphoma and multiple myeloma indications. Cost is roughly 1/3 of US pricing, delivered at qualifying tertiary centres.
Sources
- GLOBOCAN 2022 cancer incidence estimates (IARC/WHO)
- National Cancer Center of China Cancer Statistics 2024
- NMPA approved oncology drug registry 2025
- Partner-network 2026 international-patient oncology quote data
Last reviewed: 2026-05-12.
Going beyond the report
For a written quote from two Class A international departments — covering procedure, hospital match, recovery and visa — start the quote wizard.